Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13053750 | 0.87 | CA1 (0.37) | CA1CA2CA9CA12CA4 | |
| SCHEMBL13081342 | 0.83 | CA1 (0.34) | CA1CA2CA9 | |
| SCHEMBL13053852 | 0.81 | CA1 (0.34) | CA1CA2CA9 | |
| SCHEMBL13053764 | 0.80 | CA1 (0.30) | CA1CA2CA9 | |
| SCHEMBL12712881 | 0.78 | CA2 (0.36) | CA1CA2CA9CA12CA4 | |
| SCHEMBL13053794 | 0.78 | HCRTR1 (0.33) | CA1CA2CA9CA4CA5A | |
| SCHEMBL13053796 | 0.77 | CYP1A2 (0.31) | — | |
| SCHEMBL13053760 | 0.75 | CA1 (0.34) | CA1CA2CA9CA4CA5A | |
| SCHEMBL12712574 | 0.74 | CA1 (0.34) | CA1CA2CA9CA12CA4 | |
| SCHEMBL12712878 | 0.72 | CA1 (0.33) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383609-B2 | Phosphorus containing heterocyclic compounds, sugar analogues, and compositions having anti-cancer activity containing the same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-02-26 | — | — | US | disclosed |
| US-20100298272-A1 | PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS, SUGAR ANALOGUES, AND COMPOSITIONS HAVING ANTI-CANCER ACTIVITY CONTAINING THE SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298272-A1 | PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS, SUGAR ANALOGUES, AND COMPOSITIONS HAVING ANTI-CANCER ACTIVITY CONTAINING THE SAME | G6PC1, SLC5A1, HK1 | CA1 494/4885CA2 182/4885CA9 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.